Major Histocompatibility Complex class I peptide-binding groove (MHC-I peptide-binding groove)

The MHC class I peptide-binding groove is a specialized structural domain within the Major Histocompatibility Complex class I (MHC-I) molecule, primarily formed by the α1 and α2 helices of the heavy chain (NIH, 2023). Its fundamental biological role is to bind and present short, endogenously derived peptides (typically 8–10 amino acids) to the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes (PubMed, 2021). This presentation is essential for the immune system to distinguish between 'self' and 'non-self,' enabling the detection of virally infected or malignant cells (StatPearls, 2023). In various diseases, the groove's allelic polymorphism influences susceptibility to autoimmune conditions, such as the association between HLA-B27 and ankylosing spondylitis, and plays a critical role in cancer immune surveillance (NIH, 2023). Therapeutic interventions often target this site through peptide vaccines designed to occupy the groove with tumor-specific antigens or through engineered molecules like soluble TCRs and TCR-mimic antibodies that recognize specific peptide-MHC complexes to trigger targeted cell killing (PubMed, 2022).

Other names

MHC-I peptide-binding cleftHLA class I peptide-binding pocketAntigen-binding grooveMHC-I binding cleftHLA-I peptide-binding groove

Peptide loading and presentation to CD8+ T cells; recognition of the peptide-MHC complex by engineered T-cell receptors (TCRs) or TCR-mimic antibodies to induce targeted cytotoxicity (NIH, 2023; PubMed, 2022).